The system will be going down for regular maintenance. Please save your work and logout.
Blood polyunsaturated omega‐3 fatty acids, brain atrophy, cognitive decline, and dementia risk
Language
EN
Article de revue
This item was published in
Alzheimer's and Dementia. 2020-10
English Abstract
Introduction: We searched for consistent associations of an omega-3 index in plasma (sum of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) with several dementia-related outcomes in a large cohort of older ...Read more >
Introduction: We searched for consistent associations of an omega-3 index in plasma (sum of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) with several dementia-related outcomes in a large cohort of older adults. Methods: We included 1279 participants from the Three-City study, non-demented at the time of blood measurements at baseline, with face-to-face neuropsychological assessment and systematic detection of incident dementia over a 17-year follow-up. An ancillary study included 467 participants with up to three repeated brain imaging exams over 10 years. Results: In multivariable models, higher levels of plasma EPA+DHA were consistently associated with a lower risk of dementia (hazard ratio for 1 standard deviation = 0.87 [95% confidence interval, 0.76–0.98]), and a lower decline in global cognition (P =.04 for change over time), memory (P =.06), and medial temporal lobe volume (P =.02). Discussion: This prospective study provides compelling evidence for a relationship between long-chain omega-3 fatty acids levels and lower risks for dementia and related outcomes. © 2020 the Alzheimer's AssociationRead less <
